Potential role of MicroRNA 200c gene expression in assessment of colorectal cancer

Tayel, Safaa I.; Fouda, Eman Abd-allah Mahmoud; Gohar, Suzy; Elshayeb, Elsayed I.; El-sayed, Eman H.; El-Kousy, Salah M.

doi:10.1016/j.abb.2018.04.009

Cited by 9 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tayel et al also reported that CEA was superior than CA19-19 in CRC according to ROC curve analysis. 40 To the best of our knowledge, our current study is the first one that evaluated the lncRNA ASB16-AS1 in patients with CRC. Additionally, the lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 were assessed for the first time in both plasma and tissue specimens of CRC patients.…”

Section: Discussionmentioning

confidence: 96%

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

Elabd¹,

Soliman²,

El-Hamouly³

et al. 2022

TACG

View full text Add to dashboard Cite

Background:We aimed to evaluate the diagnostic roles of AFAP1-AS1 and ASB16-AS1 in colorectal cancer and highlight their roles in predicting colorectal cancer patients' prognosis. Methods: In this case-control study, 146 participants were involved. Group I included 47 patients with CRC. Group II composed of 49 patients with benign lesions in the colon, and Group III included 50 apparently normal subjects of coincided age and gender as controls. All participants were subjected to clinical and endoscopic evaluations, CA19-9, CEA, and quantification of relative expression of lncRNAs ASB16-AS1 and AFAP1-AS1. Results: CRC patients had significantly elevated expression levels of both lncRNAs in tissue and plasma samples versus benign and control groups (p < 0.001). Despite the higher sensitivity of tissue samples results, the relative expression of both lncRNAs in plasma samples was very encouraging in the discrimination between patients with CRC versus control and benign groups. Furthermore, both lncRNAs could discriminate patients with early-stage CRC (stage I&II) from being colonic lesion and control groups with better sensitivity and specificity presented by ASB16-AS1 in tissue and plasma than results detailed by AFAP1-AS1. High expression levels of ASB16-AS1 in tissue and plasma and tissue lncRNA AFAP1-AS1 are significantly correlated with decreased overall survival (p < 0.001) and reduced progression-free (p < 0.001) compared to low expression in CRC patients. Conclusion:We propose the utilization of lncRNA ASB16-AS1 and lncRNA AFAP1-AS1 as biomarkers in diagnosis and prognosis estimation for CRC patients. Moreover, their value in early CRC patients may affect the assortment of target therapy and treatment protocols.

show abstract

Section: Discussionmentioning

confidence: 96%

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

Elabd¹,

Soliman²,

El-Hamouly³

et al. 2022

TACG

View full text Add to dashboard Cite

show abstract

“…As the miR-200 family is located at two distinct chromosomal locations, complete family in vivo knockout is difficult and has only very recently been accomplished in vitro with knockout cells showing increases in senescence and EMT signaling genes with similar expression patterns found in gastric cancer patient RNA-seq samples [213]. The abnormal regulation of the miR-200 family as a whole has been indicated as a marker for CRC in serum/plasma [208,214], and as individual miRNAs: miR-200a [215], miR-200b [89], miR-200c [86,[97][98][99][100][101], miR-141 [89,98,99,101,216], and miR-429 [102]. Furthermore, elevated serum levels of miR-200c and miR-141 have been correlated with an increased CRC metastasis [97,99] and poor prognoses in CRC patients [97,[99][100][101]216].…”

Section: Mir-200 Familymentioning

confidence: 99%

“…The abnormal regulation of the miR-200 family as a whole has been indicated as a marker for CRC in serum/plasma [208,214], and as individual miRNAs: miR-200a [215], miR-200b [89], miR-200c [86,[97][98][99][100][101], miR-141 [89,98,99,101,216], and miR-429 [102]. Furthermore, elevated serum levels of miR-200c and miR-141 have been correlated with an increased CRC metastasis [97,99] and poor prognoses in CRC patients [97,[99][100][101]216]. Lowered miR-200a and elevated miR-200b in serum show similar patterns of being correlated with poor outcomes in CRC patients [89,211].…”

Section: Mir-200 Familymentioning

confidence: 99%

MicroRNAs and ‘Sponging’ Competitive Endogenous RNAs Dysregulated in Colorectal Cancer: Potential as Noninvasive Biomarkers and Therapeutic Targets

Jorgensen

2022

IJMS

View full text Add to dashboard Cite

The gastrointestinal (GI) tract in mammals is comprised of dozens of cell types with varied functions, structures, and histological locations that respond in a myriad of ways to epigenetic and genetic factors, environmental cues, diet, and microbiota. The homeostatic functioning of these cells contained within this complex organ system has been shown to be highly regulated by the effect of microRNAs (miRNA). Multiple efforts have uncovered that these miRNAs are often tightly influential in either the suppression or overexpression of inflammatory, apoptotic, and differentiation-related genes and proteins in a variety of cell types in colorectal cancer (CRC). The early detection of CRC and other GI cancers can be difficult, attributable to the invasive nature of prophylactic colonoscopies. Additionally, the levels of miRNAs associated with CRC in biofluids can be contradictory and, therefore, must be considered in the context of other inhibiting competitive endogenous RNAs (ceRNA) such as lncRNAs and circRNAs. There is now a high demand for disease treatments and noninvasive screenings such as testing for bloodborne or fecal miRNAs and their inhibitors/targets. The breadth of this review encompasses current literature on well-established CRC-related miRNAs and the possibilities for their use as biomarkers in the diagnoses of this potentially fatal GI cancer.

show abstract

“…The prognostic impact of miRNA-200 family has been described in several studies focused on CRC [37,65,66,67]. Chen et al showed that high plasma miR-141 levels were significantly associated with a poor OS in metastatic CRC patients [37].…”

Section: Mirnas As Prognostic Biomarkers In Crcmentioning

confidence: 99%

Circulating microRNAs as Promising Biomarkers in Colorectal Cancer

Rapado‐González

Álvarez-Castro

López‐López

et al. 2019

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers and a leading cause of cancer-related deaths worldwide. Despite numerous advances in therapeutic approaches, this cancer has a poor prognosis when it is diagnosed at late stages. Therefore, the scientific effort is nowadays directed towards the development of new non-invasive and dynamic biomarkers to improve the survival expectancy of CRC patients. In this sense, deregulated expression of many miRNAs has been shown to play an important role for CRC carcinogenesis and dissemination. Noticeably, an increasing number of studies highlight that circulating miRNAs, including those traveling inside exosomes or those released by tumor cells into circulation, constitute a promising tool for early detection, prognosis and therapy selection of CRC. Therefore, in this review we focus on the clinical potential of blood circulating miRNAs as emerging biomarkers with high value to improve the clinical management of CRC patients, providing a deep and complete perspective of the realities and challenges to translate these biomarkers to the clinical context.

show abstract

Potential role of MicroRNA 200c gene expression in assessment of colorectal cancer

Cited by 9 publications

References 16 publications

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

MicroRNAs and ‘Sponging’ Competitive Endogenous RNAs Dysregulated in Colorectal Cancer: Potential as Noninvasive Biomarkers and Therapeutic Targets

Circulating microRNAs as Promising Biomarkers in Colorectal Cancer

Contact Info

Product

Resources

About